Potential therapeutic targets for Mpox: the evidence to date

Byrareddy, Siddappa N; Sharma, Kalicharan; Sachdev, Shrikesh; Reddy, Athreya S.; Acharya, Arpan; Klaustermeier, Kaylee M.; Lorson, Christian L; Singh, Kamal

doi:10.1080/14728222.2023.2230361

Cited by 6 publications

(2 citation statements)

References 131 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This natural advantage makes NIOCH-14 promising candidate for future wide-ranging applications. 100 , 173 – 175 The current round of Mpox outbreak is highly mutable and still evolving. Although Tecovirimat is effective in current clinical use, it may pose a risk of resistance in the future.…”

Section: The Life Cycle Of Mpox Virus and The Discovery Of Anti-mpox ...mentioning

confidence: 99%

Mpox (formerly monkeypox): pathogenesis, prevention and treatment

Lu,

Xing,

Wang

et al. 2023

Sig Transduct Target Ther

View full text Add to dashboard Cite

In 2022, a global outbreak of Mpox (formerly monkeypox) occurred in various countries across Europe and America and rapidly spread to more than 100 countries and regions. The World Health Organization declared the outbreak to be a public health emergency of international concern due to the rapid spread of the Mpox virus. Consequently, nations intensified their efforts to explore treatment strategies aimed at combating the infection and its dissemination. Nevertheless, the available therapeutic options for Mpox virus infection remain limited. So far, only a few numbers of antiviral compounds have been approved by regulatory authorities. Given the high mutability of the Mpox virus, certain mutant strains have shown resistance to existing pharmaceutical interventions. This highlights the urgent need to develop novel antiviral drugs that can combat both drug resistance and the potential threat of bioterrorism. Currently, there is a lack of comprehensive literature on the pathophysiology and treatment of Mpox. To address this issue, we conducted a review covering the physiological and pathological processes of Mpox infection, summarizing the latest progress of anti-Mpox drugs. Our analysis encompasses approved drugs currently employed in clinical settings, as well as newly identified small-molecule compounds and antibody drugs displaying potential antiviral efficacy against Mpox. Furthermore, we have gained valuable insights from the process of Mpox drug development, including strategies for repurposing drugs, the discovery of drug targets driven by artificial intelligence, and preclinical drug development. The purpose of this review is to provide readers with a comprehensive overview of the current knowledge on Mpox.

show abstract

Section: The Life Cycle Of Mpox Virus and The Discovery Of Anti-mpox ...mentioning

confidence: 99%

Mpox (formerly monkeypox): pathogenesis, prevention and treatment

Lu,

Xing,

Wang

et al. 2023

Sig Transduct Target Ther

View full text Add to dashboard Cite

show abstract

“…Rogers et al have explored the utilization of silver nanoparticles, both polysaccharide-coated and non-coated, with varying diameters, as well as silver nitrate at different concentrations, as inhibitors for Mpox infectivity [92]. Other viral inhibition mechanisms are represented by RNA interference in which the expression of target genes is inhibited by the attack of exogenous genes [93][94][95].…”

Section: Future Perspectivesmentioning

confidence: 99%

Antivirals against Monkeypox (Mpox) in Humans: An Updated Narrative Review

Bruno,

Buccoliero

2023

Life

View full text Add to dashboard Cite

As of 29 August 2023, a total of 89,596 confirmed cases of Mpox (monkeypox) have been documented across 114 countries worldwide, with 157 reported fatalities. The Mpox outbreak that transpired in 2022 predominantly affected young men who have sex with men (MSM). While most cases exhibited a mild clinical course, individuals with compromised immune systems, particularly those living with HIV infection and possessing a CD4 count below 200 cells/mm3, experienced a more severe clinical trajectory marked by heightened morbidity and mortality. The approach to managing Mpox is primarily symptomatic and supportive. However, in instances characterized by severe or complicated manifestations, the utilization of antiviral medications becomes necessary. Despite tecovirimat’s lack of official approval by the FDA for treating Mpox in humans, a wealth of positive clinical experiences exists, pending the outcomes of ongoing clinical trials. Brincidofovir and cidofovir have also been administered in select cases due to the unavailability of tecovirimat. Within the scope of this narrative review, our objective was to delve into the clinical attributes of Mpox and explore observational studies that shed light on the utilization of these antiviral agents.

show abstract